The Fly

Editas Medicine assumed with a Neutral at Credit Suisse

Credit Suisse analyst Richard Law assumed coverage of Editas Medicine with a Neutral rating and $13 price target. The analyst states that he is assuming a 70% probability of favorable final appeal ruling for Broad/MIT from the U.S. federal appeals court, which would give the company "monopolistic IP control of CRISPR/Cas9 editing in the U.S." Law further notes that he assigns "little value" to Editas’ lead asset EDIT-301 as he does not believe that the company could demonstrate differentiated benefits that are "clinically meaningful".

Published first on TheFly

See today’s best-performing stocks on TipRanks >>

Read More on EDIT:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More